Last updated on April 20, 2014 at 21:20 EDT

Medicago is Awarded Contract from the U.S. Department of Defence for Potential Future Production

January 7, 2013

QUEBEC CITY, Jan. 7, 2013 /PRNewswire/ – Medicago Inc. (TSX: MDG; OTCQX:
MDCGF), a biopharmaceutical company focused on developing highly
effective and competitive vaccines based on proprietary manufacturing
technologies and Virus-Like Particles (VLPs), today announced that it
has been awarded an Indefinite Delivery / Indefinite Quantity (ID/IQ)
contract from the Defense Advanced Research Projects Agency (DARPA)
based on Medicago having met all the technical requirement standards
for the contract. As a result of Medicago having met these requirements
and standards, Medicago is now allowed to bid for the manufacture and
delivery of certain tobacco-produced proteins, for which Medicago has
already demonstrated a proven ability. Medicago intends to bid on these
orders when solicitations are next issued by the U.S. government and
may be awarded production contracts.

“This contract is important as Medicago is now listed as a company
meeting all of DARPA’s rigorous technical requirements,” said Mike
Wanner, Executive Vice President of Operations at Medicago. “This fits
Medicago’s revenue-generation model nicely as we can leverage our
cost-effective commercial production facility in North Carolina to bid
for production orders when they are issued by the U.S. government.”

Medicago USA, Inc. was previously awarded a US$21 million non-dilutive
Technology Investment Agreement with DARPA for a proof of concept
demonstration to produce 10 million doses of a vaccine candidate in 30
days.  The DARPA project was successfully completed in July of 2012,
for which Medicago USA Inc. successfully completed every milestone
including the production of more than 10 million doses of immunogenic
vaccine in less than 30 calendar days as qualified by animal studies.

Medicago’s pipeline includes:

        --  The initiation of a U.S. Phase IIa clinical trial for a
            quadrivalent seasonal flu vaccine with interim data expected in
            summer of 2013;
        --  a Phase I clinical trial for an H5N1 VLP vaccine with a new
            adjuvant that is ongoing in partnership with the Infectious
            Disease Research Institute (IDRI).  Interim data are expected
            in the first quarter of 2013;
        --  a new clinical trial of the H5N1 VLP vaccine designed to
            determine the lowest possible dose by two different
            administration routes (IM and ID) and combining the vaccine
            with a GLA adjuvant is planned to start in spring of 2013, with
            interim data expected in summer of 2013;
        --  GMP process development and a GLP toxicology study for a rabies
            vaccine are ongoing;
        --  Medicago is also working with Mitsubishi Tanabe Pharma under a
            strategic alliance to develop a vaccine for rotavirus and at
            least two additional vaccine candidates;
        --  In addition to vaccines, Medicago is conducting research and
            development in the area of biosimilar products.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements or
forward-looking information for the purposes of applicable securities
laws and such statements and information are based upon current
expectations, which involve risks and uncertainties associated with
Medicago’s business and the environment in which the business operates.
Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking, including those identified
by the expressions “anticipate”, “believe”, “plan”, “estimate”,
“expect”, “intend”, and similar expressions to the extent they relate
to Medicago or its management. The forward-looking statements are not
historical facts, but reflect Medicago’s current expectations regarding
future results or events. These forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations, including the
matters discussed under “Risk Factors and Uncertainties” in Medicago’s
Annual Information Form filed on March 29, 2012, with the regulatory
authorities. Medicago assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those reflected in the forward-looking statements.

SOURCE Medicago Inc.

Source: PR Newswire